Table 1 The distribution of demographic variables in the cohorts

Number, N (%)

20,686

13,310

20,205

Mean ± SD age, years

67.9 ± 13.2

67.7 ± 13.9

67.9 ± 13.2

Gender, N (%)

 Female

9,922 (48.0%)

6,760 (50.8%)

9,748 (48.2%)

 Male

10,764 (52.0%)

6,550 (49.2%)

10,457 (51.8%)

In/outpatients, N (%)

 Inpatients

5,300 (25.6%)

3,344 (25.1%)

5,127 (25.4%)

 Outpatients

15,386 (74.4%)

9,966 (74.9%)

15,078 (74.6%)

Concomitant and previous diagnosis, N (%)

 Diabetes

7,083 (34.2%)

0 (0.0%)

6,798 (33.6%)

 Hyperlipidemia

7,247 (35.0%)

3,662 (27.5%)

7,083 (35.1%)

 Cerebrovascular disease

3,305 (16.0%)

1,954 (14.7%)

3,198 (15.8%)

 Myocardial infarction

757 (3.7%)

275 (2.1%)

733 (3.6%)

 Angina pectoris

6,757 (32.7%)

3,555 (26.7%)

6,504 (32.2%)

 Cardiac failure

4,196 (20.3%)

2,188 (16.4%)

3,935 (19.5%)

 Renal disease

2,099 (10.1%)

971 (7.30%)

1,670 (8.30%)

 Hyperuricemia

1,921 (9.3%)

1,063 (8.0%)

1,796 (8.9%)

 Other macroangiopathy

2,249 (10.9%)

1,231 (9.2%)

2,154 (10.7%)

Antihypertensive drug use at entered period, N (%)

 ARB

9,481 (45.8%)

5,767 (43.3%)

9,271 (45.9%)

 CCB

12,497 (60.4%)

8,111 (60.9%)

12,180 (60.3%)

 ACE inhibitor

2,140 (10.3%)

1,300 (9.8%)

2,112 (10.5%)

 Other

7,174 (34.7%)

4,368 (32.8%)

6,885 (34.1%)

Other concomitant use drug at registration, N (%)

 Antidiabetic drug

2,827 (13.7%)

0 (0.0%)

2,746 (13.6%)

 Antihyperlipidemic drug

4,684 (22.6%)

2,498 (18.8%)

4,639 (23.0%)

 Antithrombotic or anticoagulant drug

6,999 (33.8%)

3,871 (29.1%)

6,801 (33.7%)